Triple-Gene is a clinical stage gene therapy company focused on developing advanced therapies for complex cardiovascular diseases.
25 million patients globally suffer from heart failure
6M patients in the U.S. affected
About every 90 seconds a person in the U.S. dies from heart disease
Developing a holistic treatment for heart failure requires improvements in angiogenesis, calcium homeostasis-associated cellular energetics, reductions in inflammatory signals, and the activation/recruitment of stem cells to support heart remodeling. We are focused on advancing targeted, controllable, and multigenic gene and cell therapies for the treatment of cardiovascular diseases.